Join us in a special edition of the Hope Webinar Series which will include a patient story: Camilla Row and her experience with ctDNA monitoring.
Dr. Dan Catenacci, GI Oncologist will present an overview of the current landscape of assays and what it means exactly. We have invited guest diagnostics industry experts to discuss on the latest developments in the market, and different applications for these technologies.
Our goal is to explaining MRD, ctDNA, RNA, NGS, and other comprehensive biomarker testing. Additionally, discuss the role of liquid biopsies in precision oncology.
This webinar is intended to educate and empower better care management for patients, caregivers, and medical professionals.
Industry Experts from:
MiRXES is a biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses. Our versatile miRNA detection platform has broad applications for discovery of cancer biomarkers and we are developing a comprehensive portfolio of early detection tests targeting gastric, lung, colorectal, breast, liver and ovarian cancer.
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. For more information, visit www.natera.com.
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor.